Early observations from Falini et al. based on 591 AML patients showed that 291 NPM1MT patients achieved a higher complete response (CR) rate and harbored less chemotherapy-refractory disease after induction therapy compared to NPM1 wild-type (NPM1WT) [8]. Here, NPM1 is linked to acute myeloid leukemia.